|
Richard M. Kostrzewa, PhD., Dr.h.c. |
Contact Information:
Department of Biomedical Sciences
James H. Quillen College of Medicine
East Tennessee State University
PO Box 70577
Johnson CIty, TN 37614
423-439-6321
kostrzew@mail.etsu.edu
Education and Professional Background:
Dr. Kostrzewa is professor of Pharmacology. He received his BS (1967) in Chemistry and MS (1967) in Pharmacology from Philadelphia College of Pharmacy and Science. He received his Ph.D. (1971) in Pharmacology from the University of Pennsylvania and was awarded Doctor Honoris Causa, 2005 from the Medical University of Silesia in Katowice Poland. Following his post-doctoral training in New Orleans he was appointed to the faculty at Louisiana State University. He joined the faculty in the department of Pharmacology at ETSU in 1978, rising to the rank of Professor in 1984. Dr. Kostrzewa is a world recognized authority in the neuropharmacological aspects of Parkinson Disease and ADHD, with a primary focus on Serotoninergic, histaminergic and dopaminergic systems.
Veterans Administration Medical Center in New Orleans LA (1971-75);
Adjunct Faculty, Department of Pharmacology, Tulane University Medical Center, New Orleans LA (1972-76);
Adjunct Faculty, University of New Orleans (1972-78);
Department of Physiology, LSU Medical Center, New Orleans LA (1975-78);
Department of Pharmacology (1978-2012), Department of Biomedical Sciences (2012- ), Quillen College of Medicine, East Tennessee State University, Johnson City, TN
Research Interest:
• Dopamine/Serotonin systems in Parkinson’s Disease
• Dopamine Receptor Supersensitization and ADHD
• Dopamine D-2 Receptors and Oral Dyskinesia/Tardive Dyskinesia
Experimental approaches are directed towards neuronal mechanisms associated with dopaminergic and serotoninergic system involvement in selected behavioral outcomes attending neurological disorders.
Active Research funding:
These studies have been or are supported by NINDS and Eli Lilly Co.
Selected Publications:
Kostrzewa RM, JP Kostrzewa, RA Kostrzewa, P Nowak and R Brus (2008) Pharmacological models of ADHD. J. Neural Transm. 115, 287-298.
Kostrzewa RM, L Antkiewicz-Michaluk and F Fornai (2010) Dopaminergic nerves as targets for neurotoxins, In: Neurotoxicology, Target Organ Toxicity Series, 3rd Edition (Harry J and H Tilson, Eds.) (Informa Health Care, New York, NY), pp. 112-137. [ISBN: 9781420054873]
Nowak P, RA Kostrzewa, D Skaba and RM Kostrzewa (2010) Acute L-DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of Parkinsonian rats. Neurotox. Res. 17(3), 299-304.
Kostrzewa RM, Kostrzewa JP, Kostrzewa RA, Kostrzewa FP, Brus R, Nowak P (2011) Stereotypic progressions in psychotic behavior. Neurotox. Res. 19: 243-252.
Archer T, Kostrzewa RM (2012) Physical exercise alleviates ADHD symptoms: regional deficits and development trajectory. Neurotox Res. 21(2):195-209.
Kostrzewa RM, FP Kostrzewa (2012) Neonatal 6-hydroxydopamine lesioning enhances quinpirole-induced vertical jumping in rats that were quinpirole-primed during postnatal ontogeny. Neurotox Res. 21(2):231-235.
Brown RW, Maple, AM, Perna MK, Sheppard AB, Cope ZA, Kostrzewa, RM (2012?) Schizophrenia and substance abuse comorbidity: Nicotine addiction and the neonatal quinpirole model. Dev. Neurosci. Review. (accepted, Apr 2012)
Kostrzewa RM (2013) Tardive dyskinesia: outcome of antipsychotic treatment and brain damage? Handbook of Neurotoxicity (Kostrzewa RM, Editor), Springer New York. (accepted Oct 10, 2012)
Chen J, RM Kostrzewa, X Xu (2013) “Necroptosis, a potential therapeutic target for neurological disorders”. In Handbook of Neurotoxicity (Kostrzewa RM, Editor) (Springer, New York NY), Section on Selective Neurotoxins (RM Kostrzewa, Section Editor).